Dataset Information

Genotype-phenotype correlation in PRKN-associated Parkinson's disease.

ABSTRACT: Bi-allelic pathogenic variants in PRKN are the most common cause of autosomal recessive Parkinson's disease (PD). 647 patients with PRKN-PD were included in this international study. The pathogenic variants present were characterised and investigated for their effect on phenotype. Clinical features and progression of PRKN-PD was also assessed. Among 133 variants in index cases (n = 582), there were 58 (43.6%) structural variants, 34 (25.6%) missense, 20 (15%) frameshift, 10 splice site (7.5%%), 9 (6.8%) nonsense and 2 (1.5%) indels. The most frequent variant overall was an exon 3 deletion (n = 145, 12.3%), followed by the p.R275W substitution (n = 117, 10%). Exon3, RING0 protein domain and the ubiquitin-like protein domain were mutational hotspots with 31%, 35.4% and 31.7% of index cases presenting mutations in these regions respectively. The presence of a frameshift or structural variant was associated with a 3.4 ± 1.6 years or a 4.7 ± 1.6 years earlier age at onset of PRKN-PD respectively (p < 0.05). Furthermore, variants located in the N-terminus of the protein, a region enriched with frameshift variants, were associated with an earlier age at onset. The phenotype of PRKN-PD was characterised by slow motor progression, preserved cognition, an excellent motor response to levodopa therapy and later development of motor complications compared to early-onset PD. Non-motor symptoms were however common in PRKN-PD. Our findings on the relationship between the type of variant in PRKN and the phenotype of the disease may have implications for both genetic counselling and the design of precision clinical trials.

SUBMITTER: Menon PJ

PROVIDER: S-EPMC10980707 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Genotype-phenotype correlation in PRKN-associated Parkinson's disease.

Menon Poornima Jayadev PJ Sambin Sara S Criniere-Boizet Baptiste B Courtin Thomas T Tesson Christelle C Casse Fanny F Ferrien Melanie M Mariani Louise-Laure LL Carvalho Stephanie S Lejeune Francois-Xavier FX Rebbah Sana S Martet Gaspard G Houot Marion M Lanore Aymeric A Mangone Graziella G Roze Emmanuel E Vidailhet Marie M Aasly Jan J Gan Or Ziv Z Yu Eric E Dauvilliers Yves Y Zimprich Alexander A Tomantschger Volker V Pirker Walter W Álvarez Ignacio I Pastor Pau P Di Fonzo Alessio A Bhatia Kailash P KP Magrinelli Francesca F Houlden Henry H Real Raquel R Quattrone Andrea A Limousin Patricia P Korlipara Prasad P Foltynie Thomas T Grosset Donald D Williams Nigel N Narendra Derek D Lin Hsin-Pin HP Jovanovic Carna C Svetel Marina M Lynch Timothy T Gallagher Amy A Vandenberghe Wim W Gasser Thomas T Brockmann Kathrin K Morris Huw R HR Borsche Max M Klein Christine C Corti Olga O Brice Alexis A Lesage Suzanne S Corvol Jean Christophe JC

NPJ Parkinson's disease 20240329 1

Bi-allelic pathogenic variants in PRKN are the most common cause of autosomal recessive Parkinson's disease (PD). 647 patients with PRKN-PD were included in this international study. The pathogenic variants present were characterised and investigated for their effect on phenotype. Clinical features and progression of PRKN-PD was also assessed. Among 133 variants in index cases (n = 582), there were 58 (43.6%) structural variants, 34 (25.6%) missense, 20 (15%) frameshift, 10 splice site (7.5%%), ...[more]

PMID: 38553467

Similar Datasets

Project description:BackgroundMutations in LRRK2, the gene that encodes leucine-rich repeat kinase 2, are a cause of Parkinson's disease (PD). The International LRRK2 Consortium was established to answer three key clinical questions: can LRRK2-associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2?MethodsResearchers from 21 centres across the world collaborated on this study. The frequency of the common LRRK2 Gly2019Ser mutation was estimated on the basis of data from 24 populations worldwide, and the penetrance of the mutation was defined in 1045 people with mutations in LRRK2 from 133 families. The LRRK2 phenotype was defined on the basis of 59 motor and non-motor symptoms in 356 patients with LRRK2-associated PD and compared with the symptoms of 543 patients with pathologically proven idiopathic PD.FindingsSix mutations met the consortium's criteria for being proven pathogenic. The frequency of the common LRRK2 Gly2019Ser mutation was 1% of patients with sporadic PD and 4% of patients with hereditary PD; the frequency was highest in the middle east and higher in southern Europe than in northern Europe. The risk of PD for a person who inherits the LRRK2 Gly2019Ser mutation was 28% at age 59 years, 51% at 69 years, and 74% at 79 years. The motor symptoms (eg, disease severity, rate of progression, occurrence of falls, and dyskinesia) and non-motor symptoms (eg, cognition and olfaction) of LRRK2-associated PD were more benign than those of idiopathic PD.InterpretationMutations in LRRK2 are a clinically relevant cause of PD that merit testing in patients with hereditary PD and in subgroups of patients with PD. However, this knowledge should be applied with caution in the diagnosis and counselling of patients.FundingUK Medical Research Council; UK Parkinson's Disease Society; UK Brain Research Trust; Internationaal Parkinson Fonds; Volkswagen Foundation; National Institutes of Health: National Institute of Neurological Disorders and Stroke and National Institute of Aging; Udall Parkinson's Disease Centre of Excellence; Pacific Alzheimer Research Foundation Centre; Italian Telethon Foundation; Fondazione Grigioni per il Morbo di Parkinson; Michael J Fox Foundation for Parkinson's Research; Safra Global Genetics Consortium; US Department of Veterans Affairs; French Agence Nationale de la Recherche.

Dataset Information

Genotype-phenotype correlation in PRKN-associated Parkinson's disease.

Publications

Genotype-phenotype correlation in PRKN-associated Parkinson's disease.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets